In contrast, patients with clinical PAD were less likely to receive angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs) (82, 90, and 94%, p for trend = 0.007). Here, ACE is linked to peripheral arterial disease.